{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:23:14Z","timestamp":1773080594704,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Brain metastasis from colorectal cancer was more common in patients with HER2 amplification. Here, we document a 53-year-old male with HER2-amplified rectal cancer and brain metastases, treated with Trastuzumab Deruxtecan (T-Dxd, 5.4 mg\/kg) plus bevacizumab (7.5 mg\/kg) every three weeks as third line therapy. The patient achieved a partial response with a progression-free-survival of 7 months, highlighting the potential of T-Dxd. Adverse events included grade 3 thrombocytopenia, grade 2 neutropenia, and grade 1 fatigue. Our report emphasizes the rarity of brain metastases in colorectal cancer and illustrates a favorable response to T-Dxd plus bevacizumab.<\/jats:p>","DOI":"10.3389\/fonc.2025.1714422","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:33Z","timestamp":1764739233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: T-Dxd plus bevacizumab in a patient with brain metastases from rectal cancer with HER2 amplification"],"prefix":"10.3389","volume":"15","author":[{"given":"Yanan","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisha","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinduo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2022.05.08","article-title":"Colorectal cancer burden, trends and risk factors in China: A review and comparison with the United States","volume":"34","author":"Li","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway human epidermal growth factor receptor 2 basket study: pertuzumab + Trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2-altered advanced solid tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2200306","DOI":"10.1200\/PO.22.00306","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31125","article-title":"Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3","volume":"124","author":"Ross","year":"2018","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy067","article-title":"Molecular landscape of ERBB2\/ERBB3 mutated colorectal cancer","volume":"110","author":"Loree","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad200","article-title":"Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer: A systematic literature review and meta-analysis of clinical outcomes","volume":"28","author":"Bekaii-Saab","year":"2023","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1379","article-title":"Negative hyperselection of patients with HER2+ and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study","volume":"30","author":"Randon","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy156","article-title":"HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients","volume":"29","author":"Tan","year":"2018","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.019","article-title":"HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study","volume":"181","author":"Chen","year":"2023","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02569-4","article-title":"HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study","volume":"130","author":"Prete","year":"2024","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5021","article-title":"Breast cancer brain metastasis: Current evidence and future directions","volume":"12","author":"Sun","year":"2023","journal-title":"Cancer Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-015-9795-z","article-title":"Bevacizumab in combination with chemotherapy for colorectal brain metastasis","volume":"47","author":"Finkelmeier","year":"2016","journal-title":"J Gastrointest Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0571","article-title":"Central nervous system as possible site of relapse in ERBB2-positive metastatic colorectal cancer: long-term results of treatment with trastuzumab and lapatinib","volume":"6","author":"Sartore-Bianchi","year":"2020","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6813","DOI":"10.3390\/ijms22136813","article-title":"Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer","volume":"22","author":"Guarini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/2326-6066.CIR-21-0870","article-title":"Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition","volume":"10","author":"Alvarez-Breckenridge","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2441101","article-title":"MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer","volume":"21","author":"Strickler","year":"2025","journal-title":"Future Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1714422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:34Z","timestamp":1764739234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1714422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1714422"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1714422","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1714422"}}